Rezolute IncChange company Symbol lookupSelect an option...RZLT Rezolute IncESTC Elastic NVCMBM Cambium Networks CorpS SentinelOne IncBAC Bank of America CorpSDA SunCar Technology Group IncRAIN Rain Oncology IncEOI Eaton Vance Enhanced Equity Income FundOLNCF Omni Lite Industries Canada IncRGNX Regenxbio IncGo
Rezolute, Inc. (Rezolute) is a clinical-stage biopharmaceutical company, which is engaged in developing therapies for metabolic diseases related to chronic glucose imbalance. The Company’s lead clinical asset, RZ358, is an intravenously administered human monoclonal antibody that binds to a unique site (allosteric) on the insulin receptor in insulin target tissues, such as in the liver, fat, and muscle. The antibody modifies insulin’s binding and signaling to maintain glucose levels in a normal range, which counteracts the effects of elevated insulin in the body. It is a potential treatment for congenital hyperinsulinism (HI), which is an ultra-rare pediatric genetic disorder characterized by excessive production of insulin by the pancreas in Phase II. The Company is also developing RZ402, an oral plasma kallikrein inhibitor (PKI) being developed as a potential therapy for the chronic treatment of diabetic macular edema (DME) in Phase I.
|
|
|
|
| |
Company Profile
Rezolute, Inc. (Rezolute) is a clinical-stage biopharmaceutical company, which is engaged in developing therapies for metabolic diseases related to chronic glucose imbalance. The Company’s lead clinical asset, RZ358, is an intravenously administered human monoclonal antibody that binds to a unique site (allosteric) on the insulin receptor in insulin target tissues, such as in the liver, fat, and muscle. The antibody modifies insulin’s binding and signaling to maintain glucose levels in a normal range, which counteracts the effects of elevated insulin in the body. It is a potential treatment for congenital hyperinsulinism (HI), which is an ultra-rare pediatric genetic disorder characterized by excessive production of insulin by the pancreas in Phase II. The Company is also developing RZ402, an oral plasma kallikrein inhibitor (PKI) being developed as a potential therapy for the chronic treatment of diabetic macular edema (DME) in Phase I.
Valuation Ratios
- Price/Earnings (TTM)
- --
- Price/Sales (TTM)
- --
- Price/Book (MRQ)
- 0.57x
- Price/Cash Flow (TTM)
- --
MRQ = Most Recent Quarter
Price Performance
Financial Statements
Balance sheet
Values displayed are in thousands.
Income statement
Values displayed are in thousands.
Cash flow
Values displayed are in thousands.
Company Officers
- Young-Jin KimChmn.
- Nevan Charles ElamCEO
- Sankaram Mantripragada
- Brian K. RobertsOther
- Philippe Fauchet
Address
- 275 Shoreline Drive, Suite 500
- Redwood City, CA 94065
- Phone: (650) 206-4507
- Fax: (302) 636-5454
- https://www.rezolutebio.com/
Insider Trading
No insider trading activity.
Insider trading information report provided by Copyright © 2023. All rights reserved.
Reuters content is the intellectual property of Reuters. Any copying, republication or redistribution of Reuters content, including by caching, framing or similar means, is expressly prohibited without the prior written consent of Reuters. Reuters is not liable for any errors or delays in content, or for any actions taken in reliance on any content. Reuters, Reuters Logo and the Sphere Logo are trademarks and registered trademarks of the Reuters Group of companies around the world.
Data is provided for information purposes only and is not intended for trading purposes. Reuters shall not be liable for any errors or delay in the content, or for any action taken in reliance on any content. The RIC or Reuters Instrument Code set has been developed and maintained by Reuters and is the intellectual property of Reuters.